IPO Watch
A real-time look at every biotech IPO filed and the amount raised in all the world’s indexes. Compiled by editor Max Gelman.
Our Plans
Free
COMPANIES
RAISED
Traditional IPOs
0
0
SPACs
0
0
TOTAL
0
0
Edit Content
2024
| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| Septerna Therapeutics (NASDAQ: SEPN) | G protein-coupled receptor (GPCR); Therapeutics | J.P. Morgan Securities, Cantor Fitzgerald, TD Securities, Wells Fargo Securities | 10/24/2024 | $18.00 | $288 million | $18 |
| Baylis Medical (TSX: BAY) | Medical devices; Cardiac electrophysiology | RBC Capital Markets, National Bank Financial, Stifel GMP | 10/09/2024 | CAD$15.00 | CAD$94.5 million | CAD$14–16 |
| Tranzyme Pharma (NASDAQ: TZYM) | Small molecule therapeutics; Cardiometabolic diseases | J.P. Morgan Securities, SVB Securities, Wedbush Securities | 09/26/2024 | $16.00 | $30 million | $14–16 |
| Spero Therapeutics (NASDAQ: SPRO) | Anti-infectives; Bacterial infections | J.P. Morgan Securities, Jefferies, Stifel GMP | 08/29/2024 | $14.00 | $55.75 million | $13–15 |
| Atturo Health (NASDAQ: ATTU) | Digital therapeutics; Pain management | Roth Capital Partners, Aegis Capital, Maxim Group | 08/15/2024 | $10.00 | $20 million | $9–11 |
| UroGen Pharma (NASDAQ: URGN) | Urology-focused therapeutics | Goldman Sachs & Co., J.P. Morgan Securities, Piper Sandler | 07/25/2024 | $17.00 | $200 million | $15–18 |
| Alder Biopharmaceuticals (NASDAQ: ALDR) | Monoclonal antibodies; Migraine treatment | Credit Suisse, Barclays, BofA Securities | 06/20/2024 | $21.00 | $220 million | $19–22 |
| NeuroMetrix (NASDAQ: NURO) | Neurological diagnostics and therapeutics | Stifel GMP, Canaccord Genuity, Lake Street Capital Markets | 05/10/2024 | $13.00 | $40 million | $12–14 |
| Inozyme Pharma (NASDAQ: INZY) | Rare disease therapeutics; Enzyme replacement | J.P. Morgan Securities, Cowen, Evercore ISI | 04/17/2024 | $19.00 | $150 million | $17–20 |
| Viaskin Therapeutics (NASDAQ: VSKN) | Allergy immunotherapy; Peanut allergy | Leerink Partners, Wells Fargo Securities, William Blair | 03/30/2024 | $12.00 | $65 million | $11–13 |
2024
| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| Septerna Therapeutics (NASDAQ: SEPN) | G protein-coupled receptor (GPCR); Therapeutics | J.P. Morgan Securities, Cantor Fitzgerald, TD Securities, Wells Fargo Securities | 10/24/2024 | $18.00 | $288 million | $18 |
| Baylis Medical (TSX: BAY) | Medical devices; Cardiac electrophysiology | RBC Capital Markets, National Bank Financial, Stifel GMP | 10/09/2024 | CAD$15.00 | CAD$94.5 million | CAD$14–16 |
| Tranzyme Pharma (NASDAQ: TZYM) | Small molecule therapeutics; Cardiometabolic diseases | J.P. Morgan Securities, SVB Securities, Wedbush Securities | 09/26/2024 | $16.00 | $30 million | $14–16 |
| Spero Therapeutics (NASDAQ: SPRO) | Anti-infectives; Bacterial infections | J.P. Morgan Securities, Jefferies, Stifel GMP | 08/29/2024 | $14.00 | $55.75 million | $13–15 |
| Atturo Health (NASDAQ: ATTU) | Digital therapeutics; Pain management | Roth Capital Partners, Aegis Capital, Maxim Group | 08/15/2024 | $10.00 | $20 million | $9–11 |
| UroGen Pharma (NASDAQ: URGN) | Urology-focused therapeutics | Goldman Sachs & Co., J.P. Morgan Securities, Piper Sandler | 07/25/2024 | $17.00 | $200 million | $15–18 |
| Alder Biopharmaceuticals (NASDAQ: ALDR) | Monoclonal antibodies; Migraine treatment | Credit Suisse, Barclays, BofA Securities | 06/20/2024 | $21.00 | $220 million | $19–22 |
| NeuroMetrix (NASDAQ: NURO) | Neurological diagnostics and therapeutics | Stifel GMP, Canaccord Genuity, Lake Street Capital Markets | 05/10/2024 | $13.00 | $40 million | $12–14 |
| Inozyme Pharma (NASDAQ: INZY) | Rare disease therapeutics; Enzyme replacement | J.P. Morgan Securities, Cowen, Evercore ISI | 04/17/2024 | $19.00 | $150 million | $17–20 |
| Viaskin Therapeutics (NASDAQ: VSKN) | Allergy immunotherapy; Peanut allergy | Leerink Partners, Wells Fargo Securities, William Blair | 03/30/2024 | $12.00 | $65 million | $11–13 |
Edit Content
2023
| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| CARGO Therapeutics (NASDAQ: CRGX) | CAR-T; Oncology | JPM Securities, Jefferies, Cowen & Co., Truist Securities | 11/09/2023 S-1 | $15.00 | $281.25 million | $15 – $17 |
| Lexeo Therapeutics (NASDAQ: LXEO) | Alzheimer’s and Cardiovascular Diseases | JPM Securities, Leerink, Stifel, RBC Capital Markets | 11/02/2023 S-1 | $11.00 | $100 million | $13 – $15 |
| Abivax SA (NASDAQ: ABVX) | Therapeutics; Chronic Inflammatory Diseases | Morgan Stanley, Leerink, LifeSci Capital, RBC Capital Markets | 10/19/2023 F-1 | $11.60 | $216.91 million | $11.60 – $13 |
| Neumora Therapeutics (NASDAQ: NMRA) | Neuroscience Drug Development | JPM Securities, BofA Securities, Stifel, Guggenheim, RBC Capital Markets, William Blair & Co. | 09/14/2023 S-1 | $17.00 | $250.7 million | $16 – $18 |
| RayzeBio, Inc. (NASDAQ: RYZB) | Radiopharmaceutical Medicines; Oncology | JPM Securities, Jefferies, Evercore Group, Truist Securities | 09/14/2023 S-1 | $18.00 | $311 million | $16 – $18 |
| Turnstone Biologics (NASDAQ: TSBX) | Solid Tumors; Tumor Infiltrating Lymphocytes (TIL) | BofA Securities, Piper Sandler, Leerink Partners | 07/20/2023 S-1 | $12.00 | $80 million | $12 – $14 |
| Sagimet Biosciences Inc. (NASDAQ: SGMT) | Non-Alcoholic Steatohepatitis (NASH), Acne and Various Cancers; Inhibitors | Goldman Sachs, Cowen & Co., Piper Sandler, JPM Securities | 07/13/2023 S-1 | $16.00 | $85 million | $15 – $17 |
| Apogee Therapeutics, Inc. (NASDAQ: APGE) | Pulmonary and Inflammatory Diseases; Biologics | Jefferies, Cowen & Co., Stifel, Guggenheim, Wedbush Securities | 07/13/2023 S-1 | $17.00 | $300.5 million | $15 – $17 |
| ACELYRIN, INC. (NASDAQ: SLRN) | Transformative Medicines | Morgan Stanley, Jefferies, Cowen & Co., Piper Sandler | 05/04/2023 S-1 | $18.00 | $540 million | $16 – $18 |
| Mineralys Therapeutics, Inc. (NASDAQ: MLYS) | Hypertension and Cardiovascular Diseases | BofA Securities, Evercore, Stifel, Guggenheim, Credit Suisse, Wells Fargo | 02/09/2023 S-1 | $16.00 | $192 million | $14 – $16 |
| Structure Therapeutics Inc. (NASDAQ: GPCR) | Chronic Diseases; Oral Therapeutics | Jefferies, SVB Securities, Guggenheim, BMO Capital Markets | 02/02/2023 S-1 | $15.00 | $161.1 million | $13 – $15 |
2023
| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| CARGO Therapeutics (NASDAQ: CRGX) | CAR-T; Oncology | JPM Securities, Jefferies, Cowen & Co., Truist Securities | 11/09/2023 S-1 | $15.00 | $281.25 million | $15 – $17 |
| Lexeo Therapeutics (NASDAQ: LXEO) | Alzheimer’s and Cardiovascular Diseases | JPM Securities, Leerink, Stifel, RBC Capital Markets | 11/02/2023 S-1 | $11.00 | $100 million | $13 – $15 |
| Abivax SA (NASDAQ: ABVX) | Therapeutics; Chronic Inflammatory Diseases | Morgan Stanley, Leerink, LifeSci Capital, RBC Capital Markets | 10/19/2023 F-1 | $11.60 | $216.91 million | $11.60 – $13 |
| Neumora Therapeutics (NASDAQ: NMRA) | Neuroscience Drug Development | JPM Securities, BofA Securities, Stifel, Guggenheim, RBC Capital Markets, William Blair & Co. | 09/14/2023 S-1 | $17.00 | $250.7 million | $16 – $18 |
| RayzeBio, Inc. (NASDAQ: RYZB) | Radiopharmaceutical Medicines; Oncology | JPM Securities, Jefferies, Evercore Group, Truist Securities | 09/14/2023 S-1 | $18.00 | $311 million | $16 – $18 |
| Turnstone Biologics (NASDAQ: TSBX) | Solid Tumors; Tumor Infiltrating Lymphocytes (TIL) | BofA Securities, Piper Sandler, Leerink Partners | 07/20/2023 S-1 | $12.00 | $80 million | $12 – $14 |
| Sagimet Biosciences Inc. (NASDAQ: SGMT) | Non-Alcoholic Steatohepatitis (NASH), Acne and Various Cancers; Inhibitors | Goldman Sachs, Cowen & Co., Piper Sandler, JPM Securities | 07/13/2023 S-1 | $16.00 | $85 million | $15 – $17 |
| Apogee Therapeutics, Inc. (NASDAQ: APGE) | Pulmonary and Inflammatory Diseases; Biologics | Jefferies, Cowen & Co., Stifel, Guggenheim, Wedbush Securities | 07/13/2023 S-1 | $17.00 | $300.5 million | $15 – $17 |
| ACELYRIN, INC. (NASDAQ: SLRN) | Transformative Medicines | Morgan Stanley, Jefferies, Cowen & Co., Piper Sandler | 05/04/2023 S-1 | $18.00 | $540 million | $16 – $18 |
| Mineralys Therapeutics, Inc. (NASDAQ: MLYS) | Hypertension and Cardiovascular Diseases | BofA Securities, Evercore, Stifel, Guggenheim, Credit Suisse, Wells Fargo | 02/09/2023 S-1 | $16.00 | $192 million | $14 – $16 |
| Structure Therapeutics Inc. (NASDAQ: GPCR) | Chronic Diseases; Oral Therapeutics | Jefferies, SVB Securities, Guggenheim, BMO Capital Markets | 02/02/2023 S-1 | $15.00 | $161.1 million | $13 – $15 |
Edit Content
2022
| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| Acrivon Therapeutics (NASDAQ: ACRV) | Precision Oncology | Jefferies, Cowen & Co., Piper Sandler | 11/14/2022 S-1 | $12.50 | $94.38 million | $16 – $18 |
| Prime Medicine (NASDAQ: PRME) | Gene Editing | JPMorgan, Goldman Sachs, Jefferies, Morgan Stanley | 10/19/2022 S-1 | $17.00 | $175 million | $16 – $18 |
| Third Harmonic Bio (NASDAQ: THRD) | Dermal, Respiratory and Gastrointestinal Diseases; Small Molecules | Morgan Stanley, Jefferies, Cowen & Co., LifeSci Capital | 09/14/2022 S-1 | $17.00 | $185.3 million | $16 – $18 |
| PepGen Inc. (NASDAQ: PEPG) | Neuromuscular and Neurologic Diseases; Therapeutics | BofA Securities, Stifel, SVB Securities, Wedbush Securities | 05/05/2022 S-1 | $12.00 | $108 million | $13 – $15 |
| AN2 Therapeutics (NASDAQ: ANTX) | Rare, Chronic and Serious Infectious Diseases; Therapeutics | Oppenheimer & Co., Cowen & Co., SVB Leerink, Evercore | 03/24/2022 S-1 | $15.00 | $69 million | $14 – $16 |
| Arcellx, Inc. (NASDAQ: ACLX) | Cancer; Cell Therapies | Barclays Capital, BofA Securities, SVB Leerink, William Blair & Co. | 02/04/2022 S-1 | $15.00 | $142.31 million | $15 – $17 |
| Vigil Neuro (NASDAQ: VIGL) | Neurodegenerative Diseases; Cell Therapies | Morgan Stanley, Jefferies, Stifel, Guggenheim | 01/11/2022 S-1 | $14.00 | $98 million | $14 – $16 |
| Amylyx Pharmaceuticals (NASDAQ: AMLX) | Neurodegenerative Diseases; Therapeutics | Evercore, Goldman Sachs, H.C. Wainwright, SVB Leerink | 01/07/2022 S-1 | $19.00 | $190 million | $18 – $20 |
| Cincor Pharma (NASDAQ: CINC) | Neurodegenerative Diseases; Therapeutics | Evercore, Jefferies, Morgan Stanley, Oppenheimer | 01/06/2022 S-1 | $17.00 | $193.60 million | $15 – $17 |
2022
| Company Name | Therapeutic Focus; Treatment Type | Underwriters | IPO Date | Offer Price to the Public | Aggregate Offering Raise | Original Price Range |
|---|---|---|---|---|---|---|
| Acrivon Therapeutics (NASDAQ: ACRV) | Precision Oncology | Jefferies, Cowen & Co., Piper Sandler | 11/14/2022 S-1 | $12.50 | $94.38 million | $16 – $18 |
| Prime Medicine (NASDAQ: PRME) | Gene Editing | JPMorgan, Goldman Sachs, Jefferies, Morgan Stanley | 10/19/2022 S-1 | $17.00 | $175 million | $16 – $18 |
| Third Harmonic Bio (NASDAQ: THRD) | Dermal, Respiratory and Gastrointestinal Diseases; Small Molecules | Morgan Stanley, Jefferies, Cowen & Co., LifeSci Capital | 09/14/2022 S-1 | $17.00 | $185.3 million | $16 – $18 |
| PepGen Inc. (NASDAQ: PEPG) | Neuromuscular and Neurologic Diseases; Therapeutics | BofA Securities, Stifel, SVB Securities, Wedbush Securities | 05/05/2022 S-1 | $12.00 | $108 million | $13 – $15 |
| AN2 Therapeutics (NASDAQ: ANTX) | Rare, Chronic and Serious Infectious Diseases; Therapeutics | Oppenheimer & Co., Cowen & Co., SVB Leerink, Evercore | 03/24/2022 S-1 | $15.00 | $69 million | $14 – $16 |
| Arcellx, Inc. (NASDAQ: ACLX) | Cancer; Cell Therapies | Barclays Capital, BofA Securities, SVB Leerink, William Blair & Co. | 02/04/2022 S-1 | $15.00 | $142.31 million | $15 – $17 |
| Vigil Neuro (NASDAQ: VIGL) | Neurodegenerative Diseases; Cell Therapies | Morgan Stanley, Jefferies, Stifel, Guggenheim | 01/11/2022 S-1 | $14.00 | $98 million | $14 – $16 |
| Amylyx Pharmaceuticals (NASDAQ: AMLX) | Neurodegenerative Diseases; Therapeutics | Evercore, Goldman Sachs, H.C. Wainwright, SVB Leerink | 01/07/2022 S-1 | $19.00 | $190 million | $18 – $20 |
| Cincor Pharma (NASDAQ: CINC) | Neurodegenerative Diseases; Therapeutics | Evercore, Jefferies, Morgan Stanley, Oppenheimer | 01/06/2022 S-1 | $17.00 | $193.60 million | $15 – $17 |